The authors demonstrated that cathepsin S expression levels are aberrantly elevated in patients with MS, in contrast to cathepsin B. However, the value of cathepsin S and cystatin C as predictive biomarkers for disease type, response to therapy, and the development of new targeted therapies for immune-mediated disorders, such as MS, requires further validation [220]. Here, CTSB is linked to myeloid sarcoma.